Price (delayed)
$34.11
Market cap
$1.87B
P/E Ratio
1,705.5
Dividend/share
N/A
EPS
$0.02
Enterprise value
$1.83B
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for
There are no recent dividends present for SUPN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.